Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
PARSIPPANY, N.J., Sept. 27, 2017 -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that Dave Stack, chairman and chief executive officer, will testify this afternoon before President Trump’s Commission on Combating Drug Addiction and the Opioid Crisis. The Commission, led by New Jersey Governor Chris Christie, was created to study ways to combat and treat drug abuse, addiction and the opioid crisis.
The meeting, which will be held in Washington, D.C. today from 12:30 p.m. until approximately 2:30 p.m. EDT, will consist of statements to the Commission from invited government, nonprofit, and business organizations regarding Innovative Pain Management and Prevention Measures for Diversion. Discussion related to the issues raised during the invited statements will follow.
Stack will discuss the critical nature of clinician and patient access to non-opioid medications that can effectively manage postsurgical pain while reducing opioid requirements. This is especially important in light of the opioid epidemic, as research continues to demonstrate a link between opioid overprescribing in the surgical setting and the risks of long-term use and/or accumulation of excess medication in the home, creating a dangerous potential for diversion or misuse.
Today’s meeting is the third in a series of meetings of the President's Commission on Combating Drug Addiction and the Opioid Crisis. It will be open to the public through live streaming on https://www.whitehouse.gov/live.
About Pacira
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension), indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia, was commercially launched in the United States in April 2012. EXPAREL and two other products have successfully utilized DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. Additional information about Pacira is available at www.pacira.com.
Company Contact:
Pacira Pharmaceuticals, Inc.
Susan Mesco, (973) 451-4030
[email protected]
Media Contact:
Coyne Public Relations
Alyssa Schneider, (973) 588-2270
[email protected]
